Skip to content
Screener

Arcus Biosciences RCUS Common Stock Shares Issued

Common Stock Shares Issued at other companies

Merck & Co. logo
Merck & Co.MRK
3.6B0.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
1B+22.7%
Incyte logo
IncyteINCY
201M+3.5%
CTO
Citius Oncology, Inc.CTOR
93M+29.9%
Gilead Sciences logo
Gilead SciencesGILD
1.2B-0.1%
Summit Therapeutics logo
Summit TherapeuticsSMMT

Other financials

Income statement

See full
Revenue$41.0M-74.4%
Operating income-$96.0M-1,100%
Net income-$91.0M
EPS (diluted)-$0.72

Balance sheet

See full
Cash & equivalents$150.0M-39.5%
Total debt$114.0M+4.6%
Total equity$464.0M-15.5%
Total assets$924.0M-14.0%

Cash flow

See full
Operating cash flow-$119.0M+10.5%
CapEx-
Free cash flow-$119.0M+10.5%

Valuation

See full
Market cap$3.66B+275%
Enterprise value$3.62B+333%
P/S31.3×+27.5×

Profitability

See full
Operating margin-415.4%-756pp
Net margin-393.2%-663pp
FCF margin-406%

Returns & leverage

See full
Return on equity-90.8%+373pp
Debt / equity0.2×0.0×
Current ratio3.8×-0.7×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001724521-26-000044
Line itemJune 30,2026December 31,2025
Other noncurrent liabilities124135
Commitments
Stockholders’ equity:
Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 127.0 shares in 2026 and 125.3 shares in 2025 issued and outstanding2,1692,116
Accumulated deficit(1,704)(1,485)
Accumulated other comprehensive loss(1)
Total stockholders’ equity464631
Total liabilities and stockholders’ equity$924$1,139

Item 1. Financial Statements

FAQ

What is Arcus Biosciences's common stock shares issued?
Arcus Biosciences (RCUS) reported common stock shares issued of 127M in Q2 2026.
How has Arcus Biosciences's common stock shares issued changed year-over-year?
Arcus Biosciences's common stock shares issued increased by 19.4% year-over-year, from 106.4M to 127M.
What is the long-term trend for Arcus Biosciences's common stock shares issued?
Over 3 years (2022 to 2025), Arcus Biosciences's common stock shares issued has grown at a 19.8% compound annual growth rate (CAGR), from 72.9M to 125.3M.
What does common stock shares issued mean?
The total number of shares that have been authorized and distributed by the corporation since its inception. This includes shares held by the public (outstanding) as well as any shares that the company has repurchased and holds in its treasury. It represents the historical volume of equity capital creation.

Ask your AI about Arcus Biosciences's common stock shares issued.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude